Navigation Links
MIGENIX Reports First Quarter Fiscal Year 2008 Financial Results
Date:9/11/2007

rm using the effective interest method.

The foreign exchange gains and losses were nominal for each of Q1/08 and Q1/07.

Liquidity and Capital Resources

As of July 31, 2007, the Company had cash, cash equivalents and short-term investments of $12.8 million (April 30, 2007: $15.3 million) and the Company's net working capital was $12.1 million (April 30, 2007: $14.6 million). The $2.5 million decrease in net working capital from April 30, 2007 is primarily attributable to the cash loss of $2.4 million (loss excluding non-cash expenses: amortization, stock-based compensation and accretion of the convertible royalty participation units) for the three months ended July 31, 2007.

MIGENIX believes that its funds on hand at July 31, 2007, together with ongoing cost containment measures and expected interest income, are sufficient to provide for operations into the third quarter of calendar 2008 before funds received, if any, from existing or new license agreements, the exercise of warrants and options and future financing activities. The Company will continue advancing its highest priority programs while operating within an annual burn rate of $11 million to $13 million. The magnitude of spending in the Company's development programs will be dependent on the licensing status of the celgosivir program and results in the programs, and we may need to increase or decrease our annual burn rate in response to such results. MIGENIX is likely to need to raise additional funds in support of its operations and there is no assurance that such funds can be obtained

Outstanding Shares

There are currently 94,463,806 (July 31, 2007: 94,463,806; April 30, 2007: 94,237,205) common shares outstanding; 29,465 convertible royalty participation units (July 31, 2007 and April 30, 2007: 29,465); and 9,250,000 (July 31, 2007: 9,250,000; April 30, 2007: 9,350,000) preferred shares outstanding. In May 2007 the Company converted 50,000 Series A and 50,000 Series B
'/>"/>

SOURCE MIGENIX Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related biology technology :

1. TomoTherapy reports 86% revenue jump, $131M net loss in Q1
2. Sonic Foundry reports GAAP loss as Q2 revenues rise
3. Fiserv reports $113.5 million in Q1 profit
4. Third Wave reports net loss of $18.9M for 2006
5. Musicnotes reports 45 percent growth in 2006
6. Sonic Foundry reports net loss, higher revenue
7. Sonic Foundry reports first cash-positive quarter
8. Merge Healthcare reports $10.8M net loss in Q3
9. Third Wave reports $5.2M third quarter loss
10. Merge Healthcare appoints new CEO, reports $215 million Q2 loss
11. Merge files financial reports by market opening
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/26/2015)... Feb. 26, 2015   Synageva BioPharma Corp. ... company developing therapeutic products for rare disorders, today ... 2015 goals, other key objectives, and financial guidance.  ... today at 4:30 p.m. EST to review the ... To participate in today,s call by telephone, please ...
(Date:2/26/2015)... (PRWEB) February 26, 2015 On behalf ... its affiliated companies, Wilentz, Goldman & Spitzer, P.A. ... trade secrets lawsuit against Genewiz Inc. in excess of ... and utilized GenScript’s trade secrets, and that it improperly ... court entered an order denying motions for judgment notwithstanding ...
(Date:2/26/2015)... Already well respected for accuracy, HEIDENHAIN now ... Length Gauge offerings with new variants of its successful ... HEIDENHAIN’s pencil probe-style SPECTO length gauge series now offers ... 1Vpp, 12mm stroke length variants of the SPECTO series ... variant with a weak spring, 0.4N of gauging force, ...
(Date:2/26/2015)... Regis Technologies announced new potent ... drug substances. , Regis Technologies is proud to announce ... Compound Suite (PCS) for 2015. , Regis is a ... facility in Morton Grove, Illinois. The PCS addition will ... up to about one kilogram per batch. , ...
Breaking Biology Technology:Synageva BioPharma Reports 2014 Full Year Financial Results 2Synageva BioPharma Reports 2014 Full Year Financial Results 3Synageva BioPharma Reports 2014 Full Year Financial Results 4Synageva BioPharma Reports 2014 Full Year Financial Results 5Synageva BioPharma Reports 2014 Full Year Financial Results 6Synageva BioPharma Reports 2014 Full Year Financial Results 7Synageva BioPharma Reports 2014 Full Year Financial Results 8Synageva BioPharma Reports 2014 Full Year Financial Results 9Wilentz Client GenScript Awarded $10 Million in Trade Secrets Case Against Genewiz 2Wilentz Client GenScript Awarded $10 Million in Trade Secrets Case Against Genewiz 3Accuracy and Versatile Gauging Go Hand in Hand at HEIDENHAIN 2Regis Extends cGMP Services to Oncology Market 2
... could be a shot in the arm for adoptive ... and controlling the growth of T cells in living ... of the therapy,s drawbacks. The engineers altered the ... which researchers can build new functions into cells by ...
... ATHENS, Ohio (April 26, 2010) Though scientists argue ... electronics for building the next generation of faster, smaller, ... actually seen the spina quantum mechanical property of electronsin ... an Advance Online Publication in the journal Nature ...
... ... 2010 Growth , ... Chicago, IL (Vocus) April 26, 2010 -- Sword Diagnostics, Inc. , committed to ... its corporate headquarters and research facilities to accommodate planned growth. Double the size of ...
Cached Biology Technology:New technique reinforces immune cells that seek and destroy cancer, says Stanford researcher 2New technique reinforces immune cells that seek and destroy cancer, says Stanford researcher 3Physicists capture first images of atomic spin 2Life Sciences Company Sword Diagnostics Moves Operations to Chicago 2Life Sciences Company Sword Diagnostics Moves Operations to Chicago 3
(Date:2/23/2015)... Feb. 23, 2015 NXT-ID, Inc. (NASDAQ: ... a biometric authentication company focused on the growing mobile ... patent 62114357 for DISTRIBUTED VOICE DIRECTED PAYMENT ... introduces a new groundbreaking payment method. Payment accounts may ... may only be accessed if both the speech (the ...
(Date:2/12/2015)... Feb. 12, 2015 NXT-ID, Inc. (NASDAQ: ... a biometric authentication company focused on the growing mobile ... patent 62/113114 for DISTRIBUTED METHOD AND SYSTEM ... The patent further establishes NXT-ID,s position in the emerging ... portfolio the ability for multiple devices to collaborate with ...
(Date:2/5/2015)... , Feb. 5, 2015  Marken is starting ... company and has launched a new marketing campaign to ... Organization (CLO).  The new campaign focuses on First ... protocol and shipments. The first headline in ... aligns Marken,s priorities with its client,s priorities. Marken recognizes ...
Breaking Biology News(10 mins):NXT-ID Patents Voice Directed Payments 2NXT-ID Patents Voice Directed Payments 3NXT-ID Patents Collaborative Services to Enable the "Internet of Things" 2NXT-ID Patents Collaborative Services to Enable the "Internet of Things" 3Marken Launches New Patient-Centric Campaign 2
... has hit pay dirt for Case Western Reserve University ... The researchers have created a line of patented ... that can take on the shape and size of ... trays to rubber ducky molds to clam-shell packaging molds ...
... "family tree" of genes expressed in one form of ... at the U.S. Department of Energy,s Brookhaven National Laboratory ... more amenable to biofuel production. The study, published in ... , also lays a foundation for understanding these genes, ...
... the University of Gothenburg and Stockholm University discovered a new ... radicans , evolved from a bladder wrack (Fucus vesiculosus) ancestor ... show that, from an evolutionary perspective, it was formed ... ago, and probably as recently as about 400 years ago. ...
Cached Biology News:Case Western Reserve University engineers hit pay dirt with clay mixture 2Case Western Reserve University engineers hit pay dirt with clay mixture 3Plant gene mapping may lead to better biofuel production 2
Alkaline Phosphatase Stabilizer Solution, 1 L...
The Proteome Profiler Human Phospho-MAPK Array Kit contains 4 membranes - each spotted in duplicate with 23 different MAPK antibodies....
RayBio L Series 507: RayBio Label-based Antibody Array I (1 glass slide with 2 subarrays) Class: Antibody Array Products Product Group: Antibody Array...
X-Gal, 1 g. 5-Bromo-4-chloro-3-indolyl-b-d-galactoside.Histochemical substrate for b-galactosidase, used in blue/white screening.Store at -20 C. Protect from moisture. Category: Nucleotides & Enzymes...
Biology Products: